European Growth Stocks With High Insider Ownership Expecting Up To 59% Earnings Growth

As European markets experience a lift, buoyed by the prospect of lower U.S. borrowing costs, major indices like the STOXX Europe 600 and the UK's FTSE 100 have shown positive momentum. In this environment of cautious optimism, growth companies with high insider ownership can be particularly appealing as they often indicate strong alignment between management and shareholders' interests, potentially driving robust earnings expectations.

Top 10 Growth Companies With High Insider Ownership In Europe

Click here to see the full list of 217 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

DNO (OB:DNO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: DNO ASA is involved in the exploration, development, and production of oil and gas assets across the Middle East, the North Sea, and West Africa with a market capitalization of NOK14.72 billion.

Operations: The company's revenue is primarily generated from its oil and gas activities, amounting to $792.80 million.

Insider Ownership: 13.4%

Earnings Growth Forecast: 57.8% p.a.

DNO ASA is positioned for growth with forecasted revenue increases of 30.7% annually, surpassing the Norwegian market's growth rate. The company aims to enhance its portfolio through bolt-on acquisitions and drilling activities, despite recent operational setbacks in Kurdistan. While DNO's financial position shows some strain with interest payments not well covered by earnings, it has secured a US$500 million financing facility to support its expansion strategy. Recent discoveries in the Norwegian Sea further bolster its growth prospects.

• Click here and access our complete growth analysis report to understand the dynamics of DNO.
• Our comprehensive valuation report raises the possibility that DNO is priced higher than what may be justified by its financials.

Bonesupport Holding (OM:BONEX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Bonesupport Holding AB is an orthobiologics company that develops and sells injectable bio-ceramic bone graft substitutes globally, with a market cap of SEK19.49 billion.

Operations: The company generates revenue from its Pharmaceuticals segment, amounting to SEK1.06 billion.

Insider Ownership: 10.4%

Earnings Growth Forecast: 59.7% p.a.

Bonesupport Holding is poised for strong growth, with earnings expected to rise significantly at 59.7% annually, outpacing the Swedish market. Despite a decrease in profit margins from last year, the company's revenue is forecast to grow by 25.3% per year. Recent financial results show robust sales and net income increases for Q2 2025, reflecting its potential as a growth-oriented company with substantial insider buying activity over the past three months.

• Take a closer look at Bonesupport Holding's potential here in our earnings growth report.
• Our valuation report here indicates Bonesupport Holding may be undervalued.

AlzChem Group (XTRA:ACT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AlzChem Group AG, with a market cap of €1.51 billion, develops, produces, and markets a variety of chemical specialties across Germany, the European Union, other parts of Europe, Asia, the NAFTA region, and internationally.

Operations: The company generates revenue primarily through its Specialty Chemicals segment, which accounts for €363.96 million, and its Basics & Intermediates segment, contributing €161.10 million.

Insider Ownership: 12.9%

Earnings Growth Forecast: 17.4% p.a.

AlzChem Group's earnings grew by 25% last year and are forecast to increase at 17.38% annually, surpassing the German market's growth expectations. The company trades at a significant discount to its estimated fair value, with no substantial insider trading activity reported recently. Recent financial results show an increase in Q2 sales and net income, supporting its growth trajectory. AlzChem confirmed a full-year guidance of approximately 5% organic sales growth, targeting around €580 million in revenue for 2025.

• Unlock comprehensive insights into our analysis of AlzChem Group stock in this growth report.
• Upon reviewing our latest valuation report, AlzChem Group's share price might be too optimistic.

Key Takeaways

• Click through to start exploring the rest of the 214 Fast Growing European Companies With High Insider Ownership now.
• Ready For A Different Approach? Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com